匯川技術(300124.SZ):擬成立全資子公司購買資產用於投資建設生產、研發和辦公基地
格隆匯3月16日丨匯川技術(300124.SZ)公佈,為滿足公司絲槓、工業機器人業務發展需要,兼顧公司新業務的研發和現有南京控股子公司磁之匯的研發場地及辦公需求,公司擬在南京市江寧經濟技術開發區成立全資子公司南京匯川購買南京江寧經濟技術開發集團有限公司名下的土地及房屋建(構)築物,用於投資建設生產、研發和辦公基地。
項目總投資不超過16.5億元,其中購買土地及房屋建(構)築物6.89億元,(含契税);項目建設及鋪底流動資金合計9.61億元。項目資金全部來源於公司自有或自籌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.